Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner

0 views • Oct 30, 2021

Save

Cite

Author(s)

Fatima Amanat

Published 24 Projects

Infectious Diseases Epidemiology Allergy And Immunology Immunology Covid19

Shirin Strohmeier

Published 9 Projects

Immunology Microbiology Infectious Diseases Allergy And Immunology Influenza

Wen-Hsin Lee

Published 1 Project

Microbiology

Sandhya Bangaru

Published 6 Projects

Immunology Microbiology Antibodies Influenza Influenza A Virus

Andrew B. Ward

Published 9 Projects

Immunology Microbiology Synthetic Biology Influenza Hemagglutinin Stalk

Lynda Coughlan

Published 5 Projects

Immunology Microbiology Influenza Hemagglutinin Stalk Universal Vaccine

Uploader

Florian Krammer

Published 44 Projects

Hemagglutinin Stalk Covid19 Race Kawasaki Pims

Content

Video Abstract (AI generated) (01:28)

Paper

Preprint

After first emerging in December 2019 in China, severe acute respiratory syndrome 2 (SARS-CoV-2) has since caused a pandemic leading to millions of infections and deaths worldwide. Vaccines have been developed and authorized but supply of these vaccines is currently limited. With new variants of the virus now emerging and spreading globally, it is essential to develop therapeutics that are broadly protective and bind conserved epitopes in the receptor binding domain (RBD) or the whole spike of SARS-CoV-2. In this study, we have generated mouse monoclonal antibodies (mAbs) against different epitopes on the RBD and assessed binding and neutralization against authentic SARS-CoV-2. We have demonstrated that antibodies with neutralizing activity, but not non-neutralizing antibodies, lower viral titers in the lungs when administered in a prophylactic setting in vivo in a mouse challenge model. In addition, most of the mAbs cross-neutralize the B.1.351 as well as the B.1.1.7 variants in vitro.